8. Association between controlling nutritional status score and clinical outcomes in patients with multiple myeloma
Main Article Content
Abstract
This study was conducted to determine the relationship between CONUT score and clinical outcomes in patients receiving treatment at Military Hospital 103 for multiple myeloma. A case control study was conducted on 61 patients treated for multiple myeloma at Military Hospital 103 from January 2014 to June 2024. 85.7% of patients in the CONUT ≤ 4 group had disease control compared to 73.1% of patients who had disease control in the CONUT > 4 group, with p = 0.038. Patients in the CONUT > 4 group were 2,779 times more at risk of passing than those in the CONUT ≤ 4 group. Progressions-free survival (PFS) and overall survival (OS) of the CONUT > 4 group were 11.9 months and 19.6 months, respectively, which were statistically significantly shorter compared to PFS (30.5 months) and (OS = 63.7 months) of the CONUT ≤ 4 group, with values of p = 0.041 and p = 0.002, respectively. With p = 0.018, the CONUT score's sensitivity, specificity, and AUC for predicting OS were 59.4%, 75.9%, and 0.677, respectively. CONUT score is a factor that could predict the effectiveness of treatment response and OS in patients with multiple myeloma.
Article Details
Keywords
Multiple myeloma, CONUT (Controlling Nutritional Status), Military Hospital 103
References
2. Wang H, Chen B, Shao R, Liu W, Xiong L, Li L, Lu Y. A new prediction model integrated serum lipid profile for patients with multiple myeloma. J Cancer. 2022; 13(6): 1796-1807.
3. De Ulíbarri JI, González-Madroño A, de Villar NG, González P, González B, A. Mancha, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutricion hospitalaria. 2005; 20(1): 38-45.
4. Zhang Y, Chen Q, Lu C, Yu L. Prognostic role of controlling nutritional status score in hematological malignancies. Hematology. 2022; 27(1): 653-658.
5. Okamoto S, Ureshino H, Kidoguchi K, Kusaba K, Kizuka-Sano H, Sano H, et al. Clinical impact of the CONUT score in patients with multiple myeloma. Annals of Hematology. 2020; 99: 113-119.
6. Zhou X, Lu Y, Xia J, Mao J, Wang J, Guo H. Association between baseline Controlling Nutritional Status score and clinical outcomes of patients with multiple myeloma. Cancer Biomarkers. 2021; 32(1): 65-71.
7. Xiong YY, Zhou Q, Chen L, Yu W, Zhang HB, Chen JB. Effects of Pre-Transplant CONUT and Post-Transplant MRD on Prognosis of Patients with Multiple Myeloma after Auto-HSCT. Zhongguo Shi Yan Xue Ye Xue Za Zhi. Feb 2024; 32(1): 146-154.
8. Kamiya T, Ito C, Fujita Y, Ogura S, Mizuno K, Sakurai A, et al. The prognostic value of the controlling nutritional status score in patients with multiple myeloma. Leukemia & Lymphoma. 2020; 61(8): 1894-1900.
9. Liang F, Dong XY, Tang GF, Qi K. M, Chen W, Sang W, et al. Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma. Zhonghua Xue Ye Xue Za Zhi. Apr 14 2021; 42(4): 332-337.
10. Wiernikowski JT, Bernhardt MB. Review of nutritional status, body composition, and effects of antineoplastic drug disposition. Pediatric Blood & Cancer. 2020; 67:e28207.
11. Çağliyan Ga, Hacioğlu S, Koluman B. Ü, Ilkkilic K, Nar R, Başer M. N., et al. Is CONUT score a prognostic index in patients with diffuse large cell lymphoma? Turkish Journal of Medical Sciences. 2021; 51(4): 2112-2119.
12. Cengiz1ADEF O, Kocer1ABCDEF B, Sürmeli1B S, Santicky2CE M-J, Soran A. Are pretreatment serum albumin and cholesterol levels prognostic tools in patients with colorectal carcinoma? Med Sci Monit. 2006; 12(6): CR240-247.
13. McMillan DC, Watson WS, O’Gorman P, Preston T, Scott HR, McArdle CS. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutrition and cancer. 2001; 39(2): 210-213.